Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients
Sana Sara Dastgheyb,
Kristine Kim,
Abigail Doucette,
Gary Freedman,
Payal Shah,
Igor Makhlin,
Amy Clark,
Neil Taunk
Affiliations
Sana Sara Dastgheyb
Department of Radiation Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA; Corresponding author. Perelman Center for Advanced Medicine 3400 Civic center Boulevard, PCAM 2 West Philadelphia, Philadelphia, PA, 19104, USA.
Kristine Kim
Department of Radiation Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA
Abigail Doucette
Department of Radiation Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA
Gary Freedman
Department of Radiation Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA
Payal Shah
Department of Medical Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA
Igor Makhlin
Department of Medical Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA
Amy Clark
Department of Medical Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA
Neil Taunk
Department of Radiation Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA
Trastuzumab emtansine (T-DM1) is a novel therapeutic for HER2+ breast cancer patients with residual disease after neoadjuvant chemotherapy. Concurrent radiotherapy (RT) is offered to a subset of patients based on results from the KATHERINE trial which showed a favorable safety profile. With emerging therapies that necessitate concurrent RT, we must closely follow rates of skin toxicity. Our first 35 patients who underwent concurrent T-DM1 treatment with breast/chest wall (CW) ± nodal irradiation are reported. Most patients (22/35) had grade 2+ toxicity and 3 patients had grade 3 toxicities. We add our experience with radiation dermatitis and concurrent T-DM1 to contribute to existing reports.
